



Docket No.: 112917.143US2(MER-013 US2)  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Jacques BANCHEREAU et al.

Application No.: 10/042644

Confirmation No.: 7691

Filed: January 8, 2002

Art Unit: 1646

For: METHODS FOR TREATING AUTOIMMUNE  
DISEASES IN A SUBJECT AND IN VITRO  
DIAGNOSTIC ASSAYS

Examiner: G. Chandra


\*\*\*\*\*

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

2-23-2006

Date



Farah Bushashia

\*\*\*\*\*

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:


This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: February 23, 2006

Respectfully submitted,

By 

Ann-Louise Kerner, Ph.D.


Registration No.: 33,523

WILMER CUTLER PICKERING HALE AND  
DORR LLP

60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000  
Attorney for Applicants

03/01/2006 BABRAHA1 00000048 080219 10042644

02 FC:1806 180.00 DA



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/042644-Conf. #7691
				Filing Date	January 8, 2002
				First Named Inventor	Jacques BANCHEREAU
				Art Unit	1646
				Examiner Name	G. Chandra
Sheet	1	of	3	Attorney Docket Number	112917.143US2(MER-013 US2)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-20030147889-A1	08-07-2003	Tovey	
	AB*	US-4,824,432	04-25-1989	Skurkovich et al.	
	AC*	US-4,987,071	01-22-1991	Cech et al.	
	AD*	US-5,168,053	12-01-1992	Altman et al.	
	AE*	US-5,254,678	10-19-1993	Haseloff et al.	
	AF*	US-5,959,085	09-28-1999	Garrone et al.	
	AG*	US-6,630,143	10-07-2003	Lyman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	EP-254647	01-27-1988	MITSUBISHI CHEMICAL INDUSTRIES LIMITED		
	BB	EP-360257	03-28-1990	THE BOARD OF REGENTS FOR NORTHERN ILLINOIS UNIVERSITY, BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION INCORPORATED		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Banchereau, J.; Brier, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J. "Immunology of Dendritic Cells" <u>Annual Review of Immunology</u> Vol. 18, pgs 767-811 (2000)	
	CB	Blazar, B.R.; McKenna, H.J.; Panoskaltsis-Mortari, A.; Taylor, P.A.; "Flt3 Ligand (FL) Treatment of Murine Donors Does Not Modify Graft-Versus-Host Disease (GVHD) But FL Treatment of Recipients Post-Bone Marrow Transplantation Accelerates GVHD Lethality" <u>Biology of Blood and Marrow Transplantation</u> Vol. 7, Issue 4, pgs 197-207 (2001)	
	CC	Chakrabarti, D.; Hultgren, B.; Stewart, T.A. "IFN- $\alpha$ Induces Autoimmune T Cells Through the Induction of Intracellular Adhesion Molecule-1 and B7.2" <u>Journal of Immunology</u> Vol. 157, pgs 522-528 (1996).	
	CD	Chuntharapai, A.; Lai, J.; Huang, X.; Gibbs, V.; Kim, K.J.; Presta, L.G.; Stewart, T.A. "Characterization and Humanization of Monoclonal Antibody That Neutralizes Human Leukocyte Interferon: a Candidate Therapeutic for IDDM and SLE" <u>Cytokine</u> Vol. 15, No. 5,	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/042644-Conf. #7691
				Filing Date	January 8, 2002
				First Named Inventor	Jacques BANCHEREAU
				Art Unit	1646
				Examiner Name	G. Chandra
Sheet	2	of	3	Attorney Docket Number	112917.143US2(MER-013 US2)

		pgs 250-260 (September 7, 2001).	
	CE	Ehrenstein, M.R.; McSweeney, E.; Swane, M.; Worman, C.P.; Goldstone, A.H. "Appearance of Anti-DNA Antibodies in Patients Treated with Interferon- $\alpha$ " <u>Arthritis and Rheumatism</u> Vol. 36, Issue 2, pgs. 279-280 (February 1993).	
	CF	Fabris, P.; Betterle, C.; Floreani, A.; Greggio, N.A.; de Lazzari, F. "Development of Type 1 Diabetes Mellitus During Interferon Alpha Therapy for Chronic HCV Hepatitis" <u>Lancet</u> Vol. 340, Issue 8818, pg. 548 (August 29, 1992)	
	CG	Foulis, A.K.; Farquharson, M.A.; Meager, A. "Immuno-reactive $\alpha$ -Interferon in Insulin-Secreting $\beta$ cells in Type 1 Diabetes Mellitus" <u>Lancet</u> Vol. 2, Issue 8573, pgs. 1423-1427 (December 19, 1987)	
	CH	Guerci, A.P.; Guerci, B.; Levy-Marchal, C.; Ongagna, J.; Ziegler, O. "Onset of Insulin-Dependent Diabetes Mellitus After Interferon-Alpha Therapy for Hairy Cell Leukemia" Vol. 343, Issue 8906, pgs. 1167-1168 (May 7, 1994)	
	CI	Hooks, J.J.; Moutsopoulos, H.M.; Geis, S.A.; Stahl, N.I.; Decker, J.L. "Immune Interferon in the Circulation of Patients with Autoimmune Disease" <u>New England Journal of Medicine</u> ; Vol. 301, Issue 1, pgs. 5-8 (July 5, 1979)	
	CJ	Huang, X.; Yuang, J.; Goddard, A.; Foulis, A.; James, R.F.; Lemmark, A. "Interferon Expression in the Pancreases of Patients with Type 1 Diabetes" <u>Diabetes</u> Vol. 44, Issue 6, pgs. 658-664 (June 1995)	
	CK	Kim et al., Clin. Exp. Immunol., 70: 562-269 (1987)	
	CL	Okanoue, T.; Sakamoto, S.; Itoh, Y.; Minami, M.; Yasui, K.; Sakamoto, M. "Side Effects of High-Dose Interferon Therapy for Chronic Hepatitis C" <u>Journal of Hepatology</u> Vol. 25, Issue 3, pgs. 283-291 (September 1996)	
	CM	Preble, O.T.; Rothko, K.; Klippel, J.H.; Friedman, R.M.; Johnston, M.I. "Interferon-Induced 2'-5' Adenylate Synthetase in Vivo and Interferon Production in Vitro by Lymphocytes from Systemic Lupus Erythematosus Patients With and Without Circulating Interferon" <u>Journal of Experimental Medicine</u> Vol. 157, pgs. 2140-2146 (June 1983)	
	CN	Ronnblum, L.E. et al. "Possible Induction of Systemic Lupus Erythematosus by Interferon- $\alpha$ Treatment in a Patient With a Malignant Carcinoid Tumour" <u>Journal of Internal Medicine</u> Vol. 227, Issue 3, pgs. 207-210 (March 1990)	
	CO	Ronnblom, L.E.; Alm, G.V.; Orberg, K.E. "Autoimmunity After Alpha-Interferon Therapy for Malignant Carcinoid Tumors" <u>Annals of Internal Medicine</u> , Vol. 115, Issue 3, pgs. 178-183 (August 1, 1991).	
	CP	Schilling, P.J.; Kurzrock, R.; Kantarjian, H.; Gutteran, J.U.; Talpaz, M. "Development of Systemic Lupus Erythematosus After Interferon Therapy for Chronic Myelogenous Leukemia" <u>Cancer</u> , Vol. 68, Issue 7, pgs. 1536-1537 (October 1, 1991).	
	CQ	Shiozawa, S.; Kuroki, Y.; Kim, M.; Hirohata, S.; Ogino, T. "Interferon-Alpha in Lupus Psychosis" <u>Arthritis and Rheumatism</u> Vol. 35, Issue 4, pgs. 417-422 (April 1992)	
	CR	Schmid, P.; Itin, P.; Cox, P.; McMaster, G.K.; Horisberger, M.A. "The Type I Interferon System is Locally Activated in Psoriatic Lesions" <u>Journal of Interferon Research</u> Vol. 14, Issue 5, pgs. 229-234 (October 1994)	
	CS	Spits, H.; Couwenberg, F.; Bakker, A.Q.; Weijer, K.; Uittenbogaart, C.H. "Id2 and Id3 Inhibit Development of CD34+ Stem Cells Into Predendritic Cell (Pre-DC)2 but Not Into Pre-DC1: Evidence for a Lymphoid Origin of Pre-DC-2" <u>Journal of Experimental Medicine</u> Vol. 192, Issue 12, pgs. 1775-1783 (December 18, 2000).	
	CT	Suit, B.E.; Axelrod, D.; Moutsopoulos, H.M.; Decker, J.L.; Hooks, J.J. "Detection of Anti-Interferon Antibodies in Systemic Lupus Erythematosus" <u>Clinical Experimental Rheumatology</u> Vol. 1, pgs 133-135, (1983)	
	CU	Vallin, H.; Perers, A.; Alm, G.V.; Ronnblom, L. "Anti-Double-Stranded DNA Antibodies and Immunostimulatory Plasmid DNA in Combination Mimic the Endogenous IFN- $\alpha$ Inducer in	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/042644-Conf. #7691
				Filing Date	January 8, 2002
				First Named Inventor	Jacques BANCHEREAU
				Art Unit	1646
				Examiner Name	G. Chandra
				Attorney Docket Number	112917.143US2(MER-013 US2)
Sheet	3	of	3		

		Systemic Lupus Erythematosus" Journal of Immunology Vol. 163, pgs. 6306-6313 (1999).	
	CV	von Wussow, P.; Jakschies, D.; Hochkeppel, H.; Horisberger, M. "MX Homologous Protein in Mononeuclear Cells from Patients with Systemic Lupus Erythematosus" <u>Arthritis and Rheumatism</u> Vol. 32, Issue 7, pgs. 914-918 (July 1989)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--